Back to News & Events

Innovation Manufacturing Grants

The next round of Jeff Lawrence Innovation Fund Manufacturing Grants will open on May 1, 2019!  Manufacturing Grants are designed to encourage collaboration between companies and non-profit organizations in New York State that work with the manufacturing industry.

Eligible applicants include New York State not-for-profit organizations and applicants must partner with a New York State small or medium sized (SME) manufacturer or other early-stage company with a project relevant to the manufacturing sector. For the purposes of this grant, SME is defined as a business with at least one physical establishment in New York State, and no more than 500 employees across the entire firm or enterprise worldwide.

Eligible projects will include those that are used by the applicant to assist companies with the following types of projects: adoption of new technology to enhance a process and/or product, Prototype development, Design for manufacturing, Proof-of-concept manufacturing, Manufacturing scale-up
Manufacturing-related equipment purchases [4] [5], and other projects to advance manufacturing or manufacturing capabilities

Awards will be selected in July. Visit https://fuzehub.com/manufacturing-grants/ for full details.

 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4488
                    [post_author] => 4
                    [post_date] => 2024-10-24 10:45:00
                    [post_date_gmt] => 2024-10-24 14:45:00
                    [post_content] => 

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4348 [post_author] => 4 [post_date] => 2024-01-08 14:02:46 [post_date_gmt] => 2024-01-08 19:02:46 [post_content] =>

Join us for one or both of our upcoming intensive, SBIR/STTR proposal development workshops focusing on preparing to submit to the National Institutes of Health (NIH) and the National Science Foundation (NSF) SBIR/STTR programs.

January 24-25, 2024 - National Institutes of Health
1/24: 10:00am - 11:30am, 2:00pm-3:30pm; 1/25:10:00am - 11:30am

February 1, 2024 - National Science Foundation
9:00am - 2:30pm.

Learn from our experts important information about SBIR/STTR funding and how to craft a competitive SBIR/STTR proposal that meets the unique requirements of each agency. Our NIH session will span three short sessions over two days and include STTR/SBIR program overviews and detailed explanations of the major proposal components. The NSF session will include a detailed NSF program overview and review the key elements of an NSF proposal.

Individual workshop registration fee: $15.00. NIH/NSF package $25.00. Click here to register. https://cfbsbirtrain2024a.eventbrite.com

Workshop organized by the Center for Biotechnology at Stony Brook University and Columbia Technology Ventures, content delivered by BBC Entrepreneurial Training and Consulting.

[post_title] => Virtual SBIR/STTR Workshops: NIH & NSF [post_excerpt] => Join us for one or both of our upcoming intensive, SBIR/STTR proposal development workshops focusing on preparing to submit to the National Institutes of Health (NIH) and the National Science Foundation (NSF) SBIR/STTR programs. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => virtual-sbir-sttr-workshops-nih-nsf [to_ping] => [pinged] => [post_modified] => 2024-08-22 11:36:51 [post_modified_gmt] => 2024-08-22 15:36:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4348 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2190 [post_author] => 3 [post_date] => 2016-05-05 07:00:27 [post_date_gmt] => 2016-05-05 07:00:27 [post_content] => Accelerating the development of biomedical technologies The Center for Biotechnology at Stony Brook University, on behalf of the Long Island Bioscience Hub (LIBH), has announced the recipients of the second round of funded projects under the Hub’s technology development and commercialization initiative. Funding for ten projects totaling $600,000 was awarded to applicants from the Hub’s partner institutions. Partner institutions include Stony Brook University, Cold Spring Harbor Laboratory, Brookhaven National Laboratory, and the Feinstein Institute at Northwell Health Systems. The technology development awards made available by the LIBH are specifically aimed at growing a pipeline of commercially promising biomedical technologies that can be out-licensed for further development or serve as the foundation for new company formations in the region. There are two tiers of funding, each with the goal of accelerating technology development to reach a critical development inflection point. Feasibility awards ($50,000) are designed to rapidly test the feasibility of new ideas in a “fail-fast-or-proceed” format, or to add value to existing intellectual property leading to new market applications. Proof-of-Concept Awards ($100,000) provide targeted, milestone driven support for further development, testing, and analysis of existing intellectual property. A wide range of disciplines are represented in the project awards this cycle including biomedical engineering, chemistry, biochemistry, psychiatry, molecular genetics and microbiology, and pathology and dermatology.  Eight Feasibility awards and two Proof of Concepts awards have been funded this cycle. The recipients of this round of awards are: Feasibility Awards Therapeutic for Clostridium difficile antibiotic-associated diarrheal disease – Dr. James Bliska Device for rapid, simple and highly parallel single-cell processing – Dr. Eric Brouzes Developing a small molecule drug to treat systemic C. albicans infections – Dr. Nick Carpino Next generation hedgehog inhibitor for invasive basal cell carcinoma – Dr. Jiang Chen A Novel Strategy for Recombinant AAV Vector Production for Gene Therapy – Dr. Patrick Hearing A tandem-integration-based multi-barcode method for high-throughput combinatorial screening – Dr. Sasha Levy Novel CAIX Targeted Combination Inhibitor/PET tracer to treat patients with solid tumors – Dr. Peter Smith-Jones Substrate-Assisted Tethered Inhibitors of LigA to Treat MDR Gonorrhea – Dr. Peter Tonge Proof of Concept Awards fMRI Dynamic Phantom for Improved Detection of Resting-State Brain Networks - Dr. Lilianne Mujica-Parodi Development of SMASH technology as a next-gen sequencing diagnostic for congenital heart disease - Dr. Michael Ronemus ​“The announcement of this second cycle of awards from the Long Island Bioscience Hub under the NIH-REACH program is exemplary of the increasing commercially relevant research taking place in the region” said Clinton T. Rubin, Ph.D., Distinguished Professor, Chair, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Coupled with the recent expansion of the Hub to include the Feinstein Institute and the announcement of our third “request for proposals,” the LIBH is steadily working toward its goal of accelerating the translation of these technologies from the bench to the bed side.” The main goal of the LIBH is to foster the development of therapeutics, preventatives, diagnostics, devices and research tools emerging from LIBH partner institutions that address diseases within the NIH’s mission. Download a PDF of the press release here.     [post_title] => Long Island Bioscience Hub Announces Next Funded Projects [post_excerpt] => The Center for Biotechnology, on Behalf of the Long Island Bioscience Hub (LIBH), has announced the recipients of the second round of funded projects under the Hub’s technology development and commercialization initiative. Funding for ten projects totaling $600,000 was awarded to applicants from the Hub’s partner institutions. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-bioscience-hub-announces-next-funded-projects [to_ping] => [pinged] => [post_modified] => 2016-05-05 13:47:58 [post_modified_gmt] => 2016-05-05 13:47:58 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2190 [menu_order] => 182 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3396 [post_author] => 3 [post_date] => 2019-12-06 19:14:13 [post_date_gmt] => 2019-12-06 19:14:13 [post_content] => The Federal SBIR/STTR programs award over $3 billion in high risk R&D funding annually to qualified small businesses. The process is complex but the impact of receiving millions in non-dilutive funding is worth the effort. On January 15-16, 2020, the Center for Biotechnology will be hosting a intensive, 1.5 day workshop led by  well-known program expert and trainer, Becky Aistrup, M.B.A., Managing Partner of BBC Entrepreneurial Training & Consulting LLC. This 1.5-day session focused on the National Institutes of Health (NIH) will cover program essentials and how to compete for funding. Training is open to the public and will include:
  • Current information on the SBIR/STTR programs
  • Strategies for targeting your proposal to address the mission and requirements of the NIH
  • How to approach each section of your proposal
  • Planning your commercialization strategy
  • Writing to meet the reviewers’ expectations
Dates & Times Wed, Jan 15, 2020, 8:30 AM – 4:30 PM Thu, Jan 16, 2020 8:30 AM –12:00 PM EST Location Long Island High Technology Incubator Main Conference Room 25 Health Sciences Drive Stony Brook, NY 11794 Registration Fee: $60 Space is Limited. Pre-registration is required. REGISTER ONLINE Interested participants have the opportunity to apply for partial-sponsored follow on counseling via one-on-one proposal mentoring with SBIR/STTR experts. More info here. PLEASE NOTE: This training is mandatory for those who will be submitting applications for the One-on-One proposal counseling. [post_title] => Proposal Development Workshop: SBIR/STTR for NIH [post_excerpt] => The Federal SBIR/STTR programs award over $3 billion in high risk R&D funding annually to qualified small businesses. Learn if this opportunity is right for your technology how to develop a competitive proposal at our annual workshop. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => proposal-development-workshop-sbirsttr-for-nih [to_ping] => [pinged] => [post_modified] => 2019-12-06 19:14:13 [post_modified_gmt] => 2019-12-06 19:14:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3396 [menu_order] => 82 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment would provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2024-12-05 11:35:07 [post_modified_gmt] => 2024-12-05 16:35:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

Virtual SBIR/STTR Workshops: NIH & NSF

More Information

Long Island Bioscience Hub Announces Next Funded Projects

More Information

Proposal Development Workshop: SBIR/STTR for NIH

More Information